Kestra Advisory Services LLC raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 158.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,994 shares of the biopharmaceutical company’s stock after buying an additional 4,283 shares during the quarter. Kestra Advisory Services LLC’s holdings in Alnylam Pharmaceuticals were worth $1,726,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the company. Commonwealth Equity Services LLC lifted its position in Alnylam Pharmaceuticals by 1.2% during the third quarter. Commonwealth Equity Services LLC now owns 9,930 shares of the biopharmaceutical company’s stock valued at $2,450,000 after acquiring an additional 115 shares during the last quarter. Chicago Partners Investment Group LLC grew its holdings in Alnylam Pharmaceuticals by 124.7% in the third quarter. Chicago Partners Investment Group LLC now owns 2,186 shares of the biopharmaceutical company’s stock worth $490,000 after purchasing an additional 1,213 shares during the last quarter. Rakuten Investment Management Inc. grew its holdings in Alnylam Pharmaceuticals by 13.0% in the third quarter. Rakuten Investment Management Inc. now owns 20,289 shares of the biopharmaceutical company’s stock worth $5,155,000 after purchasing an additional 2,328 shares during the last quarter. Provenance Wealth Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $527,000. Finally, GraniteShares Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 12.7% during the 3rd quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 205 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Trading Down 2.0%
Alnylam Pharmaceuticals stock opened at $156.50 on Wednesday. The stock has a 50-day moving average price of $215.05 and a 200 day moving average price of $274.10. The company has a market capitalization of $20.96 billion, a price-to-earnings ratio of 8.13 and a beta of 0.42. Alnylam Pharmaceuticals, Inc. has a 52 week low of $149.18 and a 52 week high of $479.79. The company has a quick ratio of 2.43, a current ratio of 2.48 and a debt-to-equity ratio of 0.18.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the company earned $2.90 EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current year.
Analyst Upgrades and Downgrades
ALNY has been the subject of a number of recent analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $290.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 30th. HC Wainwright reduced their target price on Alnylam Pharmaceuticals from $455.00 to $250.00 and set a “buy” rating on the stock in a research report on Tuesday. Oppenheimer reduced their target price on Alnylam Pharmaceuticals from $350.00 to $320.00 and set an “outperform” rating on the stock in a research report on Friday, October 30th. Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating for the company in a research note on Friday, October 30th. Finally, UBS Group lowered their target price on shares of Alnylam Pharmaceuticals from $550.00 to $329.00 and set a “buy” rating for the company in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $292.57.
View Our Latest Report on ALNY
Insider Buying and Selling
In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Recommended Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
